Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Fabi A, Ferretti G, Papaldo P, Salesi N, Ciccarese M, Lorusso V, Carlini P, Carpino A, Mottolese M, Cianciulli AM, Giannarelli D, Sperduti I, Felici A, Cognetti F. Fabi A, et al. Among authors: papaldo p. Cancer Chemother Pharmacol. 2006 May;57(5):615-23. doi: 10.1007/s00280-005-0116-2. Epub 2005 Sep 15. Cancer Chemother Pharmacol. 2006. PMID: 16163541 Clinical Trial.
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: papaldo p. BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482. BMC Cancer. 2012. PMID: 23083011 Free PMC article.
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A, Giannarelli D, Malaguti P, Ferretti G, Vari S, Papaldo P, Nisticò C, Caterino M, De Vita R, Mottolese M, Iacorossi L, Cognetti F. Fabi A, et al. Among authors: papaldo p. Drug Des Devel Ther. 2015 Nov 20;9:6177-83. doi: 10.2147/DDDT.S89575. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26640370 Free PMC article. Clinical Trial.
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F. Fabi A, et al. Among authors: papaldo p. Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Epub 2008 May 1. Breast. 2008. PMID: 18450443 Free article. Review.
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Papaldo P, et al. J Clin Oncol. 2003 Sep 15;21(18):3462-8. doi: 10.1200/JCO.2003.03.034. J Clin Oncol. 2003. PMID: 12972521 Clinical Trial.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F. Ferretti G, et al. Among authors: papaldo p. Oncology. 2005;69(1):35-43. doi: 10.1159/000087286. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088233 Clinical Trial.
103 results